Some advocate this vaccination, and one small study has shown a survivin based vaccine (plus α-interferon) used in 6 patients with advanced pancreatic cancer (treatment naive and pre-treated) can evoke an immune response with clinical benefit in up to 50% of patients [107]. Here, BIRC5 is linked to pancreatic neoplasm.